Abstract
Facioscapulohumeral muscular dystrophy (FSHD) is an incurable myopathy linked to over‐expression of the myotoxic transcription factor DUX4. Targeting DUX4 is the leading therapeutic approach, however it is only detectable in 0.1‐3.8% of FSHD myonuclei. How rare DUX4 drives FSHD and the optimal anti‐DUX4 strategy is unclear. We combine stochastic gene expression with compartment models of cell states, building a simulation of DUX4 expression and consequences in FSHD muscle fibres. Investigating iDUX4 myoblasts, scRNAseq and snRNAseq of FSHD muscle we estimate parameters including DUX4 mRNA degradation, transcription and translation rates and DUX4 target gene activation rates. Our model accurately recreates the distribution of DUX4 and target gene positive cells seen in scRNAseq of FSHD myocytes. Importantly we show DUX4 drives significant cell death despite expression in only 0.8% of live cells. Comparing scRNAseq of unfused FSHD myocytes to snRNAseq of fused FSHD myonuclei, we find evidence of DUX4 protein syncytial diffusion and estimate its rate via genetic algorithms. We package our model into freely available tools, to rapidly investigate consequences of anti‐DUX4 therapy.
Original language | English |
---|---|
Article number | e88345 |
Number of pages | 27 |
Journal | eLife |
Volume | 12 |
Early online date | 15 May 2023 |
DOIs | |
Publication status | Published - 22 Jun 2023 |
Bibliographical note
Funding Information:CSRB was supported by the Turing‐Roche Partnership. MVC was supported by the EPSRC Centre for Doctoral Training in Sustainable Chemical Technologies (EP/L016354/1) and Friends of FSH research (Project: An in‐silico approach to understanding DUX4 expression). JP was supported by Muscular Dystrophy UK (19GRO‐PG12‐0493) and currently by the FSHD Society (FSHD‐Winter2021‐ 4491649104). MG was supported by the Medical Research Council (MR/S002472/1) and now by SOLVE FSHD. The Zammit lab was also generously supported by Association Française contre les Myopathies.
Data availability:
All data generated or analysed during this study are publicly available or included in the manuscript, all code employed is published as part of our shiny app at 3 public domain URLs listed in the manuscript, and available at GitHub: https://github.com/MVCowley/in-silico-FSHD-muscle-fiber-tools, copy archived at Cowley, 2023.
Publisher Copyright:
© 2023, eLife Sciences Publications Ltd. All rights reserved.
Funding
? C SRB was supported by the Turing 爀Roche Partnership 堀 MVC wasp sourpted by the EPSRC Centre for ? D octoral Training in Sustainable Chemical Technologies ?EP ?L ? ? ? 氃? Z and Friends of FSH research ? 縀 Project P An in 爁?ilico approach to understanding DUX ? enx pZ r?es sJiPo was supported by Muscular ? D ystrophy UK 縃GRO 爀PG ? ? ? Z and currently byy ? thFeS FHSDH D爀 SWocinietter ? ? ? ? ? ? ? Z 堀 MG wthaes Msuepdpicoarlt eRde sbeya rch Council ?MR ?S ? ? ? 氃? Z and now by ? S OLVE FSHD 堀 The Zammit lab was also generously supported by Aoscsiation Française contre les ? M yopathies 堀 CSRB was supported by the Turing‐Roche Partnership. MVC was supported by the EPSRC Centre for Doctoral Training in Sustainable Chemical Technologies (EP/L016354/1) and Friends of FSH research (Project: An in‐silico approach to understanding DUX4 expression). JP was supported by Muscular Dystrophy UK (19GRO‐PG12‐0493) and currently by the FSHD Society (FSHD‐Winter2021‐ 4491649104). MG was supported by the Medical Research Council (MR/S002472/1) and now by SOLVE FSHD. The Zammit lab was also generously supported by Association Française contre les Myopathies.
ASJC Scopus subject areas
- General Neuroscience
- General Biochemistry,Genetics and Molecular Biology
- General Immunology and Microbiology